Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Héctor Aviña
Observed names:
H. Aviña,
Hector Avina,
Hector Aviña
Institution:
Xencor (United States)
Observed institutions:
Xencor (United States),
Astellas Pharma (United States)
OpenAlex ID:
A5034830378
Works
80
Awards
1
Enfortumab Vedotin Antibody–Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
2016
·
Pia M. Challita-Eid
, Daulet Satpayev
, et al.
·
Cancer Research
·
773
Modulation of Macropinocytosis-Mediated Internalization Decreases Ocular Toxicity of Antibody–Drug Conjugates
2018
·
Hui Zhao
, John Atkinson
, et al.
·
Cancer Research
·
156
AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML
2015
·
Daniel S. Pereira
, Claudia I. Guevara
, et al.
·
Molecular Cancer Therapeutics
·
102
Inhibition of Megakaryocyte Differentiation by Antibody–Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia
2017
·
Hui Zhao
, Sara Gulesserian
, et al.
·
Molecular Cancer Therapeutics
·
83
PDF
Development of ASG-15ME, a Novel Antibody–Drug Conjugate Targeting SLITRK6 , a New Urothelial Cancer Biomarker
2016
·
Kendall Morrison
, Pia M. Challita-Eid
, et al.
·
Molecular Cancer Therapeutics
·
77
AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
2015
·
Fernando Doñate
, Arthur Raitano
, et al.
·
Clinical Cancer Research
·
52
The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer
2016
·
Michael Mattie
, Arthur Raitano
, et al.
·
Molecular Cancer Therapeutics
·
50
AGS62P1, a Novel Anti-FLT3 Antibody Drug Conjugate, Employing Site Specific Conjugation, Demonstrates Preclinical Anti-Tumor Efficacy in AML Tumor and Patient Derived Xenografts
2015
·
Nandini Rudra-Ganguly
, Christine Lowe
, et al.
·
Blood
·
17
407 Preliminary safety, pharmacokinetics/pharmacodynamics, and antitumor activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors
2020
·
Elaine Shum
, Adil Daud
, et al.
·
Journal for ImmunoTherapy of Cancer
·
8
PDF
Abstract 574: AGS62P1, a novel site-specific antibody drug conjugate targeting FLT3 exhibits potent anti-tumor activity regardless of FLT3 kinase activation status
2016
·
Nandini Rudra-Ganguly
, Pia M. Challita-Eid
, et al.
·
Cancer Research
·
7
Abstract 2832: Development of AGS-22M6E, a novel antibody drug conjugate (ADC) targeting Nectin-4 for the treatment of solid tumors
2011
·
Daulet Satpayev
, Michael Torgov
, et al.
·
Cancer Research
·
5
Abstract 2709: Evaluation of CD37 expression and binding of AGS67E, an antibody-drug conjugate (ADC) against CD37, on white blood cells (WBCs) collected from phase I non-Hodgkin lymphoma (NHL) patients
2017
·
Sher Karki
, Hector Avina
, et al.
·
Cancer Research
·
2
Analysis of preclinical and clinical samples after treatment with a CD37 targeting antibody drug conjugate ( AGS67E ) support a high level of CD37 expression in NHL
2017
·
F. Doñate
, P. Yang
, et al.
·
Hematological Oncology
·
2
PDF
Abstract 2650: Ags67e, an anti-cd37 monomethyl auristatin e antibody (mmae) drug conjugate as a potential therapeutic for non-hodgkin's lymphoma, chronic lymphocytic leukemia and acute myeloid leukemia
2014
·
Daniel S. Pereira
, Claudia Guevara
, et al.
·
Cancer Research
·
1
Abstract 4566: AGS-1C4D4: A fully human anti-PSCA antibody inhibits tumor formation and metastasis in orthotopic models of pancreatic cancer
2011
·
Tony Navas
, Trisha Haubrich
, et al.
·
Cancer Research
·
1
Data from AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML
2023
·
Daniel S. Pereira
, Claudia I. Guevara
, et al.
Data from The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer
2023
·
Michael Mattie
, Arthur Raitano
, et al.
Supplementary Materials and Methods: Generation of IHC Reagent M15-68(2)22 from Development of ASG-15ME, a Novel Antibody–Drug Conjugate Targeting SLITRK6, a New Urothelial Cancer Biomarker
2023
·
Kendall Morrison
, Pia M. Challita-Eid
, et al.
Data from Development of ASG-15ME, a Novel Antibody–Drug Conjugate Targeting SLITRK6, a New Urothelial Cancer Biomarker
2023
·
Kendall Morrison
, Pia M. Challita-Eid
, et al.
Data from Development of ASG-15ME, a Novel Antibody–Drug Conjugate Targeting SLITRK6, a New Urothelial Cancer Biomarker
2023
·
Kendall Morrison
, Pia M. Challita-Eid
, et al.
Supplementary Figures S1-S4 and Supplementary Methods from AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML
2023
·
Daniel S. Pereira
, Claudia I. Guevara
, et al.
PDF
Supplementary Data from The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer
2023
·
Michael Mattie
, Arthur Raitano
, et al.
Supplementary Data from The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer
2023
·
Michael Mattie
, Arthur Raitano
, et al.
Supplementary methods, legends, Figures S1-S5, and Tables S1-S2 from Inhibition of Megakaryocyte Differentiation by Antibody–Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia
2023
·
Hui Zhao
, Sara Gulesserian
, et al.
Data from The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer
2023
·
Michael Mattie
, Arthur Raitano
, et al.
Show more works
View as search
Works count:
80
Citation count:
1,336
H-index:
8
I10-index:
8
Year
Topic
Type